Natasha Hill

Dr. Natasha Hill

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Cell Cycle
Verified
Journal Article
Open access
PDF file
MLMary K. Leonard
Mary K. Leonard
NHNatasha Hill
Natasha Hill
PBPaula Bubulya
Paula Bubulya
MKMadhavi P. Kadakia
Madhavi P. Kadakia
Loss of the tumor suppressor PTEN is observed in many human cancers that display increased chromosome instability and aneuploidy. The subcellular fractions of PTEN are associated with different functions that regulate cell growth, invasion and chromosome stability. In this study, we show a novel role for PTEN in regulating mitotic centrosomes. PTEN localization at mitotic centrosomes peaks between prophase and metaphase, paralleling the centrosomal localization of PLK-1 and γ-tubulin and coinciding with the time frame of centrosome maturation. In primary keratinocytes, knockdown of PTEN increased whole-cell levels of γ-tubulin and PLK-1 in an Akt-dependent manner and had little effect on recruitment of either protein to mitotic centrosomes. Conversely, knockdown of PTEN reduced centrosomal levels of pericentrin in an Akt-independent manner. Inhibition of Akt activation with MK2206 reduced the whole-cell and centrosome levels of PLK-1 and γ-tubulin and also prevented the recruitment of PTEN to mitotic centrosomes. This reduction in centrosome-associated proteins upon inhibition of Akt activity may contribute to the increase in defects in centrosome number and separation observed in metaphase cells. Concomitant PTEN knockdown and Akt inhibition reduced the frequency of metaphase cells with centrosome defects when compared with MK2206 treatment alone, indicating that both PTEN and pAkt are required to properly regulate centrosome composition during mitosis. The findings presented in this study demonstrate a novel role for PTEN and Akt in controlling centrosome composition and integrity during mitosis and provide insight into how PTEN functions as a multifaceted tumor suppressor.

12 September 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
AAAmjad A. Aljagthmi
Amjad A. Aljagthmi
NHNatasha Hill
Natasha Hill
MCMariana Cooke
Mariana Cooke
MKMarcelo G Kazanietz
Marcelo G Kazanietz
Martín AbbaMartín Abba
Martín Abba
MKMadhavi P. Kadakia
Madhavi P. Kadakia
ΔNp63α, a member of the p53 family of transcription factors, is overexpressed in a number of cancers and plays a role in proliferation, differentiation, migration, and invasion. ΔNp63α has been shown to regulate several microRNAs that are involved in development and cancer. We identified miRNA miR-320a as a positively regulated target of ΔNp63α. Previous studies have shown that miR-320a is downregulated in colorectal cancer and targets the small GTPase Rac1, leading to a reduction in noncanonical WNT signaling and EMT, thereby inhibiting tumor metastasis and invasion. We showed that miR-320a is a direct target of ΔNp63α. Knockdown of ΔNp63α in HaCaT and A431 cells downregulates miR-320a levels and leads to a corresponding elevation in PKCγ transcript and protein levels. Rac1 phosphorylation at Ser71 was increased in the absence of ΔNp63α, whereas overexpression of ΔNp63α reversed S71 phosphorylation of Rac1. Moreover, increased PKCγ levels, Rac1 phosphorylation and cell invasion observed upon knockdown of ΔNp63α was reversed by either overexpressing miR-320a mimic or Rac1 silencing. Finally, silencing PKCγ or treatment with the PKC inhibitor Gö6976 reversed increased Rac1 phosphorylation and cell invasion observed upon silencing ΔNp63α. Taken together, our data suggest that ΔNp63α positively regulates miR-320a, thereby inhibiting PKCγ expression, Rac1 phosphorylation, and cancer invasion.

1 May 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RRRachel K. Rosenstein
Rachel K. Rosenstein
DPDiana V. Pastrana
Diana V. Pastrana
GSGabriel J. Starrett
Gabriel J. Starrett
MSMatthew R. Sapio
Matthew R. Sapio
NHNatasha Hill
Natasha Hill
ECEdward W. Cowen
Edward W. Cowen

29 August 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MOMaria Orfanoudaki
Maria Orfanoudaki
ESEmily Smith
Emily Smith
NHNatasha Hill
Natasha Hill
KGKhalid A. Garman
Khalid A. Garman
IBIsaac Brownell
Isaac Brownell
CHCurtis J. Henrich
Curtis J. Henrich
A library of naturally occurring and semi-synthetic discorhabdins was assessed for their effects on Merkel cell carcinoma (MCC) cell viability. The set included five new natural products and semi-synthetic compounds whose structures were elucidated with NMR, HRMS, and ECD techniques. Several discorhabdins averaged sub-micromolar potency against the MCC cell lines tested and most of the active compounds showed selectivity towards virus-positive MCC cell lines. An investigation of structure–activity relationships resulted in an expanded understanding of the crucial structural features of the discorhabdin scaffold. Mechanistic cell death assays suggested that discorhabdins, unlike many other MCC-active small molecules, do not induce apoptosis, as shown by the lack of caspase activation, annexin V staining, and response to caspase inhibition. Similarly, discorhabdin treatment failed to increase MCC intracellular calcium and ROS levels. In contrast, the rapid loss of cellular reducing potential and mitochondrial membrane potential suggested that discorhabdins induce mitochondrial dysfunction leading to non-apoptotic cell death.

14 July 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JJJordan E. Jarvis
Jordan E. Jarvis
LMLingling Miao
Lingling Miao
PHPatrick Hallaert
Patrick Hallaert
MMMackenzie R. Martin
Mackenzie R. Martin
LCLoren Collado
Loren Collado
IBIsaac Brownell
Isaac Brownell

6 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NHNatasha Hill
Natasha Hill
DKDavid Kim
David Kim
KBKlaus J. Busam
Klaus J. Busam
ECEmily Y. Chu
Emily Y. Chu
CGClayton Green
Clayton Green
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer. Most MCC tumors contain integrated Merkel cell polyomavirus DNA (virus-positive MCC, VP-MCC) and carry a low somatic mutation burden whereas virus-negative MCC (VN-MCC) possess numerous ultraviolet-signature mutations. In contrast to viral oncogenes and sequence mutations, little is known about genomic structural variants in MCC. To identify copy number variants in commonly altered genes, we analyzed genomic DNA from 31 tumor samples using the Nanostring nCounter copy number cancer panel. Unsupervised clustering revealed three tumor groups with distinct genomic structural variant signatures. The first cluster was characterized by multiple recurrent deletions in genes such as RB1 and WT1. The second cluster contained eight VP-MCC and displayed very few structural variations. The final cluster contained one VP-MCC and four VN-MCC with predominantly genomic amplifications in genes like MDM4, SKP2, and KIT and deletions in TP53. Overall, VN-MCC contained more structure variation than VP-MCC but did not cluster separately from VP-MCC. The observation that most MCC tumors demonstrate a deletion-dominated structural group signature, independent of virus status, suggests a shared pathophysiology among most VP-MCC and VN-MCC tumors.